A Phase 1 interventional study of ORX489 Tablets and Placebo Tablets in Healthy Adult Male and Female Volunteers, sponsored by Centessa Pharmaceuticals (UK) Limited. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-25.
Sponsored by Centessa Pharmaceuticals (UK) Limited (part of Eli Lilly and Company) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Characterize the safety, tolerability and pharmacokinetics of ORX489 following single and multiple doses.
Centessa Pharmaceuticals (UK) Limited is the lead sponsor of 6 studies on the registry; 5 are open to participants now.
First submitted before Centessa Pharmaceuticals (UK) Limited became part of Eli Lilly and Company.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SAD Study in Healthy Adults: ORX489 and Placebo
Drug: ORX489 Tablets · Other: Placebo Tablets
Food-effect Evaluation in Healthy Adults: ORX489
Drug: ORX489 Tablets
MAD Study in Healthy Adults: ORX489 and Placebo
Drug: ORX489 Tablets · Other: Placebo Tablets
SAD Study in Acutely Sleep-Deprived Healthy Adults: ORX489 and Placebo
Drug: ORX489 Tablets · Other: Placebo Tablets
ORX489 Tablets
Placebo Tablets
Part A
Incidence and severity of Treatment-Emergent Adverse Events \[Safety and Tolerability\] as assessed by AEs and SAEs of oral single ascending doses of ORX489 in healthy adult participants.
Time frame: From enrollment to the Follow-Up Visit 7 days post-discharge
Part B
Incidence and severity of Treatment-Emergent Adverse Events \[Safety and Tolerability\] as assessed by AEs and SAEs of oral single ascending doses of ORX489 in the fasted and fed states
Time frame: From enrollment to the Follow-Up Visit 7 days post-discharge]
Part C
Incidence and severity of Treatment-Emergent Adverse Events \[Safety and Tolerability\] as assessed by AEs and SAEs of oral multiple ascending doses of ORX489 in healthy adult participants
Time frame: From enrollment to the Follow-Up Visit 7 days post-discharge]
Part D:
Incidence and severity of Treatment-Emergent Adverse Events \[Safety and Tolerability\] as assessed by AEs and SAEs of oral single oral doses of ORX489 in sleep-deprived healthy adult participants
Time frame: From enrollment to the Follow-Up Visit 7 days post-discharge
Cmax
Maximum Observed Plasma Concentration for ORX489 in participants receiving ORX489
Time frame: Pre-dose and multiple post-dose timepoints, up to 48 hours
Tmax
Time of Maximum Concentration for ORX489 in participants receiving ORX489
Time frame: Pre-dose and multiple post-dose timepoints, up to 48 hours
AUClast
Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for ORX489 in participants receiving ORX489
Time frame: Pre-dose and multiple post-dose timepoints, up to 48 hours
T 1/2 (terminal elimination half-life)
The time required for the terminal phase blood concentration of ORX489 to decrease by half in participants receiving ORX489
Time frame: Pre-dose and multiple post-dose timepoints, up to 48 hours
Cmax
Maximum Observed Plasma Concentration for ORX489 in participants receiving ORX489 in the fasted and fed state.
Time frame: Pre-dose and multiple post-dose timepoints, up to 48 hours
Tmax
Time of Maximum Concentration for ORX489 in participants receiving ORX489 in the fast and fed state
Time frame: Pre-dose and multiple post-dose timepoints, up to 48 hours
AUClast
Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for ORX489 in participants receiving ORX489 in the fast and fed state
Time frame: Pre-dose and multiple post-dose timepoints, up to 48 hours
T 1/2 (terminal elimination half-life)
The time required for the terminal phase blood concentration of ORX489 to decrease by half in participants receiving ORX489 in the fast and fed state
Time frame: Pre-dose and multiple post-dose timepoints, up to 48 hours
Mean sleep latency in the Maintenance of Wakefulness Test (MWT)
Mean sleep latency in the Maintenance of Wakefulness Test (MWT) for ORX489 versus placebo: MWT sleep latency ranges from 0 to 40 minutes, with higher scores indicating greater ability to stay awake
Time frame: Part D: Day 1-2
Karolinska Sleepiness Scale score
Karolinska Sleepiness Scale score for ORX489 versus placebo: 9-point scale, ranging from "extremely alert" (1) to "very sleepy, great effort keeping awake, fighting sleep
Time frame: Part D: Day 1-2
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2026; primary completion for Jun 2027, 16 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centessa Pharmaceuticals (UK) Limited →